Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot!
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
Watch video →
Olga Petryna DrPetryna
3 years 10 months ago
#acr22 #abst0003 @RheumNow RECITAL: RTX vs CYC for CTD related ILD:comparable in MCTD, CYC better for myositis related ILD. Both stabilize but not improve FVC in SSc ILD. In SSc RTX but not CYC improved skin thickness by mRss at 24 wks. better safety of RTX vs CYC #acrbest https://t.co/6Hry5hy1SS
Catherine Sims, MD DrCassySims
3 years 10 months ago
What were the most common adverse events in @pfizer funded Xeljanz for AS?
💩diarrhea
😴fatigue
🧠headache
🫀hypertension
📍weight gain
#ACR22 @RheumNow
David Liew drdavidliew
3 years 10 months ago
@vitortexas @RheumNow Observational data, no doubt some channelling! This data is not definitive, but highlights serious questions.
Our practices need to be challenged - IVMP has questionable biological plausibility, never had clear benefit, but has clear harm.
Thanks for the comment! #ACR22
Aurelie Najm AurelieRheumo
3 years 10 months ago
Association between RA and coeliac disease: CD pts = 57% higher risk of RA vs. matched non-CD pts. Risk associated w/ age aOR 2, female aOR 2.6, socioeconomic status aOR 1.2, Medicaid aOR : 1.3.
https://t.co/APdWW7f1U6
Abst #0271 #ACR22 @Rheumnow https://t.co/djriO3QMAh
Julian Segan JulianSegan
3 years 10 months ago
Neural networks can delineate different forms of inflammatory arthritis (sero+, sero- & PsA) based on structural/inflammation patterns on MRI. Required use of contrast enhancement.
Are we going to be obsolete soon @DrCMcMaster?
@RheumNow ABSR0242 #ACR22
https://t.co/JExk9HiIYu https://t.co/G2tCafE8A7
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 10 months ago
#ACR22 Abstr#0004 Macrophage Activation Syndrome is associated with Systemic JIA #arthritis but how do they link up? Mice studies show mTORC1 is a key driver. Studies needed to assess mTORC1-inhibitor e.g. rapamycin, sirolimus etc. for SJIA-related MAS @RheumNow https://t.co/sH9seK1n8u
Bella Mehta bella_mehta
3 years 10 months ago
Why are #sJIA pts prone to #MAS?
Potential new treatment target mTORC1?
mTORC1 gene signature in monocytes
Mice models and human translational studies with evidence
#ACRBest #ACR22 @rheumnow abst#0004 #stillsdisease #autoinflammatorydisease https://t.co/Q2ehfyWMKG
Julian Segan JulianSegan
3 years 10 months ago
Safety data from 9 phase 3 UPA trials (RA, PsA & AS). In 11,271 pt-yrs exposure, no increased signal for cancer (excluding NMSC) cf. ADA/MTX. NMSC was higher however.
What data (if any) would reassure people in this space?
@RheumNow ABST0292 #ACR22
https://t.co/tS5r66loqP
Aurelie Najm AurelieRheumo
3 years 10 months ago
MIRROR RCT: Pegloticase + MTX 60% response rate vs. 30% Pegloticase + PBO in uncontrolled gout patients. 1/2 patients w/ resolution of >= 1tophus in MTX gpe vs. < 1/3 in PBO. Safety profile comparable between groups.
https://t.co/oJ6kYw94L3 Abst#0001 #ACR22 @Rheumnow https://t.co/Hmeym3Cy7n
David Liew drdavidliew
3 years 10 months ago
Beautiful translational work looking at mTORC1 driving systemic JIA to MAS - a deadly escalation.
An already accessible target:
Rapamycin in sJIA a serious proposition!
ABST0004 @BostonChildrens #ACR22 @RheumNow https://t.co/fW3C5ludjc
Aurelie Najm AurelieRheumo
3 years 10 months ago
RECITAL trial: First line RTX vs. CYC in ILD 🫁 asso w/ SSc, mixed CTD or Myositis.
Primart endpoint FVC 24 wks improved in both mCTD and Myositis associated ILD but only stabilized in SSc-ILD. RTX improved skin thickness 24 wks. https://t.co/MQcqds0jYA
Abst#0003 #ACR22 @Rheumnow https://t.co/pK48716nIg
Olga Petryna DrPetryna
3 years 10 months ago
#acrbest #abst0004 #acr22 @rheumnow 🐁 model of excessive mTORC1 activation in JIA confirms unrestricted activation of mTORC1 sufficient to trigger sJIA-like syndrome including MAS w/hemophagocytosis. rapamycin prevents MAS & ⬇️ arthritis severity & bone erosion in Il1rn-/- mice https://t.co/2HSXOJ6tX8
David Liew drdavidliew
3 years 10 months ago
If rheumatologists were distributed equitably in the US, the Navajo nation should have 19 rheumatologists.
They have just one.
Very exciting scalable program to empower primary care. Enormously powerful, both there and elsewhere
ABST0005 @jrmandal @JYazdanyMD #ACR22 @RheumNow https://t.co/mOtgLomZLM
Julian Segan JulianSegan
3 years 10 months ago
Only small changes in lipid profile and no change in arterial inflammation (measured by FDG-PET) in both TNFi/MTX and triple therapy groups over a 24 week period in the TARGET trial.
What do you think could account for this? Follow-up period too short?
@RheumNow ABST0254 #ACR22 https://t.co/JMJ7WgXyJX
Dr. John Cush RheumNow
3 years 10 months ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.
